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A B S T R A C T
Background: The PIVOT trial examined whether patients with suppressed viral load on combination anti-
retroviral therapy could be safely switched long-term to ritonavir-boosted protease inhibitor (PI) monotherapy.
The main trial publication reported that only one of 296 patients allocated to PI monotherapy experienced a loss
of drug options due to protease mutations (identiﬁed by local Sanger sequencing resistance tests) likely selected
by study drug.
Objectives: To assess if we had missed low frequency mutations, using a more sensitive methodology.
Study design: We performed next generation sequencing (NGS) on all available frozen plasma samples with
VL>1000 copies/ml from patients who were randomised to PI monotherapy. Assays were performed at Public
Health England laboratories using a previously described method.
Median coverage depth was 76,000 and the threshold for detection of minority variants was 2%. Drug sus-
ceptibility was predicted using the Stanford HIVdb algorithm.
Results: 17 of 26 potential samples, all from diﬀerent patients, were identiﬁed and successfully tested. The
median viral load was 6780 copies/ml and the median time since randomisation was 43 weeks. NGS revealed
previously unidentiﬁed minority variant protease mutations (G73D, I54T, L89V) in three samples, at frequencies
ranging between 2% and 10%. None of these mutations predicted intermediate or high level resistance, the trial
primary outcome.
Discussion: This report adds to the body of evidence that ritonavir-boosted PI monotherapy, when used as a
switch strategy with prompt detection of viral load rebound and early re-introduction of combination therapy,
rarely leads to the development of clinically important protease resistance mutations.
1. Background
The UK-based PIVOT trial examined whether patients with sup-
pressed viral load (VL) on combination antiretroviral therapy could be
safely switched to ritonavir-boosted protease inhibitor (PI) mono-
therapy, with regular HIV VL monitoring and prompt reintroduction of
combination therapy for VL rebound (deﬁned as a conﬁrmed VL ≥50
copies/ml) [1]. The primary outcome in the trial was the loss of future
drug options, deﬁned as intermediate to high level resistance (predicted
from genotype) to one or more licensed drugs in contemporary use.
Resistance tests were performed at site laboratories using various
Sanger sequencing assays.
Of the 296 patients who were allocated to PI monotherapy, 105
were genotyped at least once (153 resistance tests in total), and the
primary outcome observed in six patients. Three of these six patients
had reverse transcriptase mutations but no protease mutations. In two
other patients, both of whom received darunavir monotherapy and had
no prior PI exposure, L90M was the sole protease mutation detected;
this is rarely selected de novo by darunavir and is a relatively common
transmitted mutation [2,3]. It appears therefore that only a single PI
monotherapy patient (described below, patient A) experienced a loss of
drug options due to a mutation (I50L) selected by study drug. However,
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a limitation of Sanger sequencing is its inability to detect viral variants
below a threshold of approximately 20%.
1.1. Objectives
To examine whether the main analysis of PIVOT had missed low
frequency mutations, by applying a more sensitive sequencing metho-
dology to selected stored samples.
1.2. Study design
We performed next generation sequencing (NGS) on all available
frozen plasma samples with VL>1000 copies/ml (irrespective of
whether the formal deﬁnition of virological failure was fulﬁlled) that
had been stored from patients who were randomised to PI mono-
therapy. NGS detects the same range of mutants than Sanger sequen-
cing but with much higher sensitivity. Assays were performed at Public
Health England, with sequencing performed using MiSeq Reagent Kit
version 2 (Illumina) [4]. The threshold for low-frequency variant de-
tection was set at 2%.
2. Results
Of 26 potential samples, 17 (all from diﬀerent patients) were
identiﬁed and successfully tested. One patient received atazavair, two
patients lopinavir, and 14 patients darunavir, as ritonavir-boosted
monotherapy. The median (IQR) HIV VL was 6780 (3333–10,729) co-
pies/ml, the median (IQR) time since randomisation was 43 (33–53)
weeks, and the median (IQR) interval between ﬁrst detectable VL and
the date of sample was 6 (4–8) weeks. 10 of the samples had previously
been tested by Sanger sequencing from the same blood draw; a paired
comparison showed 99.2% homology at the nucleotide level, using a
NGS variant detection level of 20%. The 7 remaining samples were from
patients who had been tested by Sanger sequencing at a diﬀerent time
point. Protease mutations were deﬁned as major or accessory, and drug
susceptibility predicted using the Stanford HIVdb algorithm (version
8.1.1) (https://hivdb.stanford.edu/).
NGS (median coverage depth 76,000, range 20,000–170,000) re-
vealed minority variant mutations in three of the 17 patients tested, all
of whom were infected with subtype C virus (Table 1). Patient A, who
received atazanavir as PI monotherapy, met the primary outcome due
to an I50L mutation (patient 5 in Table 2 in main trial report [1]). NGS
showed a previously undetected G73D mutation (frequency 10%),
predicted to confer resistance to saquinavir (i.e. Stanford penalty score
≥10), at week 57. Notably, I50L was not detected as a minority variant
at this time point despite its detection (as a mixture) by Sanger se-
quencing at week 48, and it was also absent by Sanger sequencing at
week 71. This suggests that the mutation may have been stochastic
rather than a result of drug selection pressure. The patient remained on
atazanavir monotherapy throughout the period spanned by these three
tests. The virus of patient B, who received darunavir monotherapy,
expressed the I54T mutation (frequency 2%) at 48 weeks. Para-
doxically, this mutation predicts resistance to all PIs other than dar-
unavir, again calling into question whether it actually arose from drug
selection pressure (further supported by the low level of this variant).
The L89V mutation (frequency 5%), which predicts resistance to fo-
samprenavir, was detected at 41 weeks in patient C. This patient sim-
pliﬁed treatment from lopinavir/tenofovir/emtricitabine to lopinavir
monotherapy at trial entry. Given the inability to test patients at
baseline, it is not possible to conclude whether the mutation emerged
before or after trial entry.
In summary, NGS did not identify any additional patients who met
the trial primary outcome of intermediate or high level resistance.
Furthermore, the phenotypic impact of low-level variants may be over-
estimated by the Stanford algorithm, which was developed in the
context of majority variants.
3. Discussion
This report adds to the body of evidence that ritonavir-boosted PI
monotherapy rarely leads to the emergence of protease resistance mu-
tations when used as a switch strategy with prompt detection of VL
rebound and early re-introduction of eﬀective combination therapy.
The risk may be higher in a routine clinical study setting, where
monitoring may be less intensive. However, studies of second-line PI
monotherapy in settings without VL monitoring have found that pro-
tease resistances emerges slowly [5,6] Another sensitive genotyping
method, single genome sequencing (SGS), was used in two other trials
of maintenance PI monotherapy. In the MONOI study, 9 patients who
received darunavir PI monotherapy were tested; additional protease
resistance mutations (at positions 32, 47, 50) were found on 1/50 viral
clones from one patient [7]. In the OK04 study, SGS was performed on
11 patients who received lopinavir monotherapy; additional mutations
were detected on 3/45 viral clones at positions 46 and 82 in two pa-
tients [8].
In spite of the substantial evidence of safety, PI monotherapy has
failed to achieve wide clinical acceptance as a maintenance strategy in
patients with established viral suppression, possibly due to a higher
overall risk of virological rebound compared with combination therapy.
However, recent analyses have shown that patients at lower risk of
virological rebound can be readily identiﬁed [9] and that intensiﬁca-
tion of therapy achieves rapid re-suppression without development of
resistance [1,5]. It is also important to note that PI monotherapy pre-
cludes the development of resistance to NRTIs and NNRTIs. As drugs
from these classes generally have a lower barrier to resistance, the
overall burden of resistance in the long run may be less for PI
Table 1















A TDF, FTC, EFV ATV/r 48 23,400 I50I/L, K20K/T ND ATV(H)




61 2400 None ND
B ZDV, TDF, 3TC,
FTC, EFV
DRV/r 48 35,431 ND I54T (2%; 112,532) ATV (L), LPV(L)
52 17,700 None ND
C TDF, FTC, LPV/r LPV/r 41 10,700 None L89V (5%; 98,051) FPV(PL)
ND=not done.
a All three subjects remained on same regimens from randomisation to date of resistance test samples.
b Major or accessory mutations according to Stanford HIVdb Version 8.1.1. I50L is major mutation; all other listed mutations are accessory. Values in parentheses are frequency of
mutation; depth of read at that position.
c Predicted by Stanford HIVdb Version 8.1.1, based on consensus NGS sequence (preferentially) or Sanger sequence. PL= potential low level, L= low level, H=high.
d Predicted to be susceptible to all drugs by mutations detected by Sanger sequencing.
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monotherapy than for combination therapy. Finally, recent simpliﬁca-
tion trials have shown that dual therapy regimens consisting of a PI plus
lamivudine are as eﬀective as ongoing triple therapy in terms of short-
term viral suppression [10,11]. Our ﬁnding of minimal protease re-
sistance with PI monotherapy should also generalise to these more
potent regimens.
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